ImmuPharma Cost Of Revenue from 2010 to 2024
| IMM Stock | 1.19 0.24 16.78% |
Cost Of Revenue | First Reported 2009-03-31 | Previous Quarter 58.8 K | Current Value 18.8 K | Quarterly Volatility 653 K |
Check ImmuPharma PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmuPharma PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 35.7 K, Interest Expense of 1.9 K or Selling General Administrative of 1.7 M, as well as many indicators such as . ImmuPharma financial statements analysis is a perfect complement when working with ImmuPharma PLC Valuation or Volatility modules.
ImmuPharma | Cost Of Revenue |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.